AZIGO 250 Tablet
Azithromycin 250 mg Tablet|Medicine For Throat infections,skin infections, ear infections and sexually transmitted diseases.
AZIGO 250 Tablets
The Cure That Embraces with Care
Composition:
Each Film Coated tablet contains:
Azithromycin Dihydrate IP eq to Azithromycin 250 mg
Broad spectrum bactericidal
100 % cure rates
Economical therapy costs
Greater Acid Stability
Indication Of Azithromycin 250 mg Tablet (azigo 250):
-
URTI
-
LRTI
-
Bacterial Diarrhoea
-
Typhoid
-
SSTI
Uses of Azithromycin 250 mg (Azigo 250 tablet):
Azithromycin is used to treat many different types of infections caused by bacteria, such as respiratory infections, skin infections, ear infections, and sexually transmitted diseases.
Side Effects of Azithromycin 250 mg (Azigo 250 Tablet):
GI disturbances, visual impairment and irritation; deafness, dizziness, headache, fatigue, anorexia, paraesthesia, dysgeusia, nasal congestion, sinusitis, facial swelling, periocular swelling, pruritus, rash, urticaria, arthralgia, vaginitis; inj site pain, inflammation; decreased lymphocyte count and blood bicarbonate, increased eosinophil count, transaminase levels and/or alkaline phosphatase levels. Potentially Fatal: Angioedema and cholestatic jaundice.
Drug Interactions of Azithromycin 250 mg (Azigo 250 Tablet):
Increases serum concentrations of digoxin, ciclosporin, terfenadine, hexobarbital and phenytoin. Decreased rate of absorption w/ antacids containing aluminium and magnesium. Increased risk of ergot toxicity. Potentially Fatal: Increased risk of cardiotoxicity w/ pimozide.
Contraindications of Azithromycin 250 mg (Azigo 250 Tablet):
Known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic. Coadministration w/ pimozide. History of cholestatic jaundice/hepatic dysfunction associated w/ prior use of azithromycin.
Mechanism Of Action of Azithromycin 250 mg (Azigo 250 Tablet):
Azithromycin is a semisynthetic azalide antibiotic. It blocks transpeptidation by binding to 50s ribosomal subunit of susceptible organisms and disrupting RNA-dependent protein synthesis at the chain elongation step. Absorption: Rapidly absorbed from the GI tract. Reduced by food (capsule formulation). Absolute bioavailability: Approx 34-52%. Time to peak plasma concentration: Oral tab: 2-3 hr; IV: 1-2 hr. Distribution: Extensive into the tissues (higher than those in blood), WBC (high concentrations), CSF (small amounts). Volume of distribution: 31-33 L/kg. Plasma protein binding (concentration dependent): 7-51% (oral and IV). Metabolism: Hepatic metabolism via demethylation. Excretion: Via bile (as unchanged drug and inactive metabolites); urine (approx 6% of oral dose). Terminal elimination half-life: About 68 hr.
Special Precautions for Azithromycin 250 mg (Azigo 250 Tablet) :
May increase the risk of torsades de pointes and fatal heart arrhythmias in patients w/ prolonged QT interval, low K or Mg blood levels, slow heart rate and medication treating abnormal heart rhythms. Impaired hepatic and renal function. Pregnancy and lactation. Monitoring Parameters Liver function tests, CBC w/ differential.
For Use of Registered Medical Practitioner or A Hospital Only
